+1-518-618-1030 866 - 552 - 3453 USA-Canada Toll Free
Published Date: 2016-06-14Number of Pages: 70

Viral Conjunctivitis Pipeline Drugs Market (Drug Type - FST-100 and APD-209) - Industry Analysis, Pipeline Review, Patent Analysis, and Forecast 2020 - 2023

Viral conjunctivitis therapeutics is undergoing a transitional phase. Currently, there is no drug available for the treatment of viral conjunctivitis. However, the presence of a robust pipeline indicates towards a thriving future. The global market for viral conjunctivitis pipeline drugs is likely to exhibit a thumping CAGR of 69.60% between 2020 and 2023 and reach an opportunity worth US$462.4 mn by the end of the forecast period.

The increasing investments from ophthalmic drug manufacturers for the development of efficient treatment for viral conjunctivitis, coupled with the increasing awareness among people and augmenting expenditure on healthcare, are accelerating the growth rate of this market significantly.

On the other hand, lower diagnosis rate of viral conjunctivitis is decreasing the patient pool for the treatment, causing major hindrance in the market’s growth.

Pipeline Drugs in U.S. Gain Momentum from Promising Results of Ongoing Clinical Trials

The U.K., the U.S., Germany, Australia, Japan, and Brazil are the key regional markets for viral conjunctivitis pipeline drugs. Considering the ongoing clinical trials, the U.S. is likely to occupy the leading position among these in the coming years. The major factors driving the growth in this market are promising results of the ongoing clinical trials, the increasing awareness regarding eye care among patients and medical professionals, the high cost of the drugs, and the availability of viral conjunctivitis diagnostic tests.

The U.S. market for viral conjunctivitis pipeline drugs is projected to report a CAGR of 46.50% during the period from 2020 to 2023.

APD-209 to Exceed FST-100 by 2023

APD-209 and FST-100 are the main viral conjunctivitis drugs in the pipeline. Among the two, FST-100 is projected to hold the largest share in the market by 2020. Foresight Biotherapeutics Inc. initiated the development of FST-100; however, the company was acquired by Shire Plc. in the midway. In May 2014, the drug completed its phase II clinical trial successfully and is expected to enter the phase III of clinical trials in 2016.

Presently, the APD-209 is witnessing moderate rise; however, in the coming years, it will report a higher demand than FST-100. The drug, being developed by Adenovir Pharma AB, is in its second phase of clinical trial. It is likely to enter the third phase by mid-2016.

The market for FST-100 is projected to rise at a CAGR of 27.40% between 2020 and 2023 while the APD-209 market is likely to report a CAGR of 55.0% during the same period.

Leading Players Focus on Research Activities Thanks to Escalating Demand for Targeted Drugs for Viral Conjunctivitis

On the forefront of the global viral conjunctivitis pipeline drugs market are Panoptes Pharma GES.M.B.H., Shire Plc., Allergan Plc, Novartis AG, NovaBay Pharmaceuticals Inc., Adenovir Pharma AB, NicOx S.A., and NanoViricides Inc. As the demand for targeted drugs for viral conjunctivitis is rising, leading enterprises are focusing aggressively on research activities for the development of efficient treatments as well as diagnostic tests for viral conjunctivitis. New entrants in this market are recommended to enhance their distribution networks through strategic partnerships and alliances with local distributors.

Table of Content

1. Preface
    1.1. Report Description
    1.2. Research Methodology
    1.3. Assumptions 
    1.4. Market Segmentation

2. Executive Summary
    2.1. Viral Conjunctivitis Pipeline Drugs Market Share, by Geography, (Value %), 2023
    2.2. Viral Conjunctivitis Pipeline Drugs Market: Market Snapshot

3. Viral Conjunctivitis Pipeline Drugs Market – Industry Analysis
    3.1. Introduction
           3.1.1. Sign and Symptoms 
           3.1.2. Diagnosis 
           3.1.3. Management 
    3.2. Market Dynamics
           3.2.1. Market Drivers
                   3.2.1.1. Large Unmet Needs 
                   3.2.1.2. Strong Pipeline 
           3.2.2. Restraints
                   3.2.2.1. Low diagnosis rate
                   3.2.2.2. Self-Limiting Condition 
           3.2.3. Opportunity
                   3.2.3.1. Investment in Rigorous R&D Activities
                   3.2.3.2. Strengthen Commercialization Activities
    3.3. Epidemiology 
    3.4. Patent Analysis of Pipeline Drugs 

4.  Market Segmentation – By Pipeline Drug 
    4.1. Introduction
    4.2. Market Revenue of FST-100 (SHP-640), 2020–2023, (US$ Mn)
    4.3. Market Revenue of APD-209, 2021–2023, (US$ Mn)
    4.4. Early Stage Preclinical Trials (Tabular Form)

5. Market Segmentation – By Country 
    5.1. Introduction
    5.2. U.S. Viral Conjunctivitis Pipeline Drugs Market, 2020–2023, (US$ Mn) 
    5.3. U.K Viral Conjunctivitis Pipeline Drugs Market, 2021–2023, (US$ Mn) 
    5.4. Germany Viral Conjunctivitis Pipeline Drugs Market, 2021–2023, (US$ Mn) 
    5.5. Australia Viral Conjunctivitis Pipeline Drugs Market, 2022–2023, (US$ Mn) 
    5.6. Japan Viral Conjunctivitis Pipeline Drugs Market, 2022–2023, (US$ Mn) 
    5.7. Brazil Viral Conjunctivitis Pipeline Drugs Market, 2020–2023, (US$ Mn) 

6. Recommendations

7. Company Profiles
    7.1. Adenovir Pharma AB
    7.2. Allergan plc
    7.3. NanoViricides, Inc.
    7.4. Shire plc
    7.5. NovaBay Pharmaceuticals, Inc.
    7.6. Novartis AG
    7.7. Panoptes Pharma GES.M.B.H.
    7.8. NicOx S.A. 

List of Figures

FIG. 1 Viral Conjunctivitis Pipeline Drugs Market Share, by Geography, (Value %), 2023 (E)
FIG. 2 Industry Analysis: Viral Conjunctivitis Pipeline Drugs Market
FIG. 3 Viral Conjunctivitis: Signs and Symptoms
FIG. 4 Market Revenue of FST-100, (US$ Mn), 2020–2023
FIG. 5 Market Revenue of APD-209, (US$ Mn), 2021–2023
FIG. 6 U.S. Viral Conjunctivitis Pipeline Drugs Market Revenue, (US$ Mn), 2020–2023
FIG. 7 U.K. Market Revenue, (US$ Mn), 2021–2023
FIG. 8 Germany Market Revenue, (US$ Mn), 2021–2023
FIG. 9 Australia Market Revenue, (US$ Mn), 2022–2023
FIG. 10 Japan Market Revenue, (US$ Mn), 2022–2023
FIG. 11 Brazil Market Revenue, (US$ Mn), 2020–2023
FIG. 12 Allergan Financial Overview: (US$ Mn), 2012–2014
FIG. 13 NanoViricides, Inc., Financial Overview: (US$ Mn), 2013–2015
FIG. 14 Shire plc, Financial Overview: (US$ Mn), 2013–2015
FIG. 15 NovaBay Pharmaceuticals, Inc., Financial Overview: (US$ Mn), 2013–2015
FIG. 16 Novartis AG, Financial Overview: (US$ Mn), 2013–2015
FIG. 17 NicOx S.A., Financial Overview: (US$ Mn), 2013–2015 

List of Tables

TABLE 1 Viral Conjunctivitis Pipeline Drugs Market: Market Snapshot
TABLE 2 Viral Conjunctivitis: Management 
TABLE 3 Epidemiology
TABLE 4 Patent Analysis of Pipeline Drugs
TABLE 5 Viral Conjunctivitis Pipeline Drugs Market Revenue, by Pipeline Drug, (US$ Mn), Expected Launch–2023
TABLE 6 Early Stage Preclinical Trials
TABLE 7 Viral Conjunctivitis Pipeline Drugs Market Revenue, by Country, (US$ Mn), 2020–2023

This report analyzes the current and future prospects of the viral conjunctivitis pipeline drugs market across major countries. Viral conjunctivitis is a highly contagious disease; however, not a single drug has been approved by the U.S. FDA to treat it. Hence, demand for these drugs for viral conjunctivitis is likely to increase after their expected launch.

The research is a combination of primary and secondary research. Primary research formed the bulk of our research efforts with information collected from telephonic interviews and interactions via e-mails. Secondary research involved study of company websites, annual reports, press releases, stock analysis presentations, and various international and national databases. The report provides estimated market size in terms of US$ Mn for each drug for the period from expected launch to 2023, considering the macro and micro environmental factors. Growth rates for each drug within the market have been determined after a thorough analysis of current scenario, demographics, epidemiological study, future trends, competition with other pipeline drugs, and regulatory requirements.

The market report comprises an elaborate executive summary, which includes a market snapshot that provides information about various segments of the market. It also provides information and data analysis of the market with respect to market segments based on the drug and geographic analysis. Based on pipeline drug, the market has been segmented into FST-100 and APD-209. Market size estimations involved in-depth study of both the drugs and product information. Additionally, market related factors such as product innovation, number of viral conjunctivitis patients in various countries, and expected launch date were taken into consideration while estimating the market size. The report also provides the compound annual growth rate (CAGR %) for each market segment for the forecast period from expected launch to 2023.

Based on geography, the market has been analyzed for major countries: the U.S., the U.K., Germany, Australia, Japan, and Brazil. The market forecast for each of these countries has been provided for the period from expected launch in the country to 2023, along with their respective CAGRs for the forecast period from expected launch to 2023. The countries are selected based on ongoing clinical trial for FST-100 and APD-209.

A detailed qualitative analysis of factors responsible for driving and restraining the market and opportunities have been provided in the market overview section. This section of the report also provides epidemiological data and patent analysis of pipeline drugs, with a thorough analysis of the overall competitive scenario in the viral conjunctivitis pipeline drugs market.

A list of recommendations has been provided for new entrants to assist them in taking strategic initiatives to establish a strong presence in the market. The report also profiles major players in the market based on various attributes such as company overview, financial overview, product portfolio, business strategies, and recent developments. The viral conjunctivitis pipeline drugs market is highly consolidated. Major companies profiled in this market report are Adenovir Pharma AB, Allergan plc, NanoViricides, Inc., Shire plc, NovaBay Pharmaceuticals, Inc., Novartis AG, Panoptes Pharma GES.M.B.H., and NicOx S.A.

The viral conjunctivitis pipeline drugs market has been segmented as follows:

  • Viral Conjunctivitis Pipeline Drugs Market, by Drug
    • FST-100
    • APD-209
  • Viral Conjunctivitis Pipeline Drugs Market, by Country
    • U.S.
    • U.K.
    • Germany
    • Australia
    • Japan
    • Brazil


 
 
Back To Top